ArticleIndian journal of ophthalmology2023

Response to commentary on: A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's ranibizumab with Lucentis in patients with neovascular age-related macular degeneration.

Chirag Shah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.